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Abstract
Background: Many common and relevant diseases affecting equine welfare have yet to be tested regarding
structural variants such as copy number variations (CNVs). CNVs make up a substantial proportion of total genetic
variability in populations of many species, resulting in more sequence differences between individuals than SNPs.
Associations between CNVs and disease phenotypes have been established in several species, but equine CNV
studies have been limited. Aim of this study was to identify CNVs and to perform a genome-wide association
(GWA) study in Friesian horses to identify genomic loci associated with insect bite hypersensitivity (IBH), a common
seasonal allergic dermatitis observed in many horse breeds worldwide.
Results: Genotypes were obtained using the Axiom® Equine Genotyping Array containing 670,796 SNPs. After
quality control of genotypes, 15,041 CNVs and 5350 CNV regions (CNVRs) were identified in 222 Friesian horses.
Coverage of the total genome by CNVRs was 11.2% with 49.2% of CNVRs containing genes. 58.0% of CNVRs were
novel (i.e. so far only identified in Friesian horses). A SNP- and CNV-based GWA analysis was performed, where
about half of the horses were affected by IBH. The SNP-based analysis showed a highly significant association
between the MHC region on ECA20 and IBH in Friesian horses. Associations between the MHC region on ECA20
and IBH were also detected based on the CNV-based analysis. However, CNVs associated with IBH in Friesian horses
were not often in close proximity to SNPs identified to be associated with IBH.
Conclusions: CNVs were identified in a large sample of the Friesian horse population, thereby contributing to our
knowledge on CNVs in horses and facilitating our understanding of the equine genome and its phenotypic
expression. A clear association was identified between the MHC region on ECA20 and IBH in Friesian horses based
on both SNP- and CNV-based GWA studies. These results imply that MHC contributes to IBH sensitivity in Friesian
horses. Although subsequent analyses are needed for verification, nucleotide differences, as well as more complex
structural variations like CNVs, seem to contribute to IBH sensitivity. IBH should be considered as a common disease
with a complex genomic architecture.
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Background
Genome sequence diversity can be present in various
forms ranging from single-nucleotide polymorphisms
(SNPs) to structural variants such as copy number vari-
ation (CNV). CNVs, a term that refers to a change in
the number of copies of a genomic segment, are respon-
sible for more sequence differences between individuals
than SNPs and are considered to be a major source of
inter-individual genetic variation contributing to differ-
ences in phenotypes (e.g. [1, 2]). Like SNPs, CNVs can
be used to identify associations with genetic diseases and
other important complex traits. CNVs explain variable
penetrance of Mendelian and polygenic diseases and are
responsible for variation in phenotypic expression of
complex traits [e.g. 1, 2]. Considerable advances regard-
ing CNVs have been made during the last decade [2].
Several studies identified copy number variations in
horses using different techniques [3–12]. Part of these
studies tried to establish associations between CNVs and
a specific trait, a disease or even gene expression [3, 5–
12]. Most of these studies found either no association or
inconclusive associations as the number of horses with
phenotypic information or with specific CNVs were lim-
ited. For example, a 62 kb duplication on Equus caballus
(ECA) chromosome 10 seemed to be related to recur-
rent laryngeal neuropathy [5]. However, this duplication
was detected in two unphenotyped parents and only 10
out of 234 cases (representing three breeds), but in none
of the 228 controls [5]. The number of horses (between
4 to 70) studied by Doan and colleagues [3], Ghosh and
colleagues [6], Wang and colleagues [11], Ghosh and
colleagues [7], Park and colleagues [10] and McQueen
and colleagues [8] was likely too few to be able to estab-
lish associations between CNVs and the investigated
complex phenotypes. Pawlina-Tyszko and colleagues
[12] identified an association between CNVs and equine
sarcoids as these structural variants were overrepre-
sented in sarcoid cells compared to unaltered skin tissue
samples from 16 horses. Metzger and colleagues [9] per-
formed a CNV-based genome-wide association (GWA)
study in 717 horses from 17 breeds and showed that
three CNV regions on ECA1, ECA8 and ECA9 were
significantly associated with equine body size. To our
knowledge, significant associations between CNVs and
a specific trait in horses using a genome-wide ap-
proach have only been detected by Metzger and col-
leagues [9], an achievement likely accomplished
because they investigated a large sample (n = 717) and
their trait of interest (body size) may not have been
as complex as most of the diseases investigated to
date (reflected by a substantial heritability of the
trait). Many common and relevant diseases affecting
equine welfare and other traits of importance have
not yet been tested based on structural variants.
One such disease is insect bite hypersensitivity (IBH),
a seasonal allergic dermatitis observed in many horse
breeds worldwide. The hypersensitive reaction to bites
of Culicoides spp. causes an intense itch that results in
self-inflicted trauma. Common clinical symptoms are
hair loss, thickened skin, scaling and even open wounds
(e.g. [13]). The welfare and commercial value of affected
horses is therefore seriously reduced. Moreover, owners
from affected horses suffer economic losses mostly due
to an attempt to alleviate the itch and treat clinical
symptoms.
The aetiology of IBH is multifactorial in origin and in-
volves both environmental and genetic factors. Both her-
itability estimates (e.g. [14, 15]) and previous GWA
studies [16–19] showed that the inheritance of IBH is
truly polygenic in nature. Several breed-specific loci
were identified, while across-breed associations with
IBH were located on ECA7, 9, 11 and 20 [16–18]. Sev-
eral candidate genes have been examined for an associ-
ation with IBH in various breeds. However, associations
with IBH were not often established or were inconsistent
across breeds [20–22]. In contrast, the major histocom-
patibility complex (MHC, or equine lymphocyte antigens
(ELA) in horses) class I and II regions on ECA20 were
repeatedly associated with IBH in several horse breeds
[21–25] and with allergen-specific immunoglobulin E
levels against two moulds [26].
Most GWA studies in horses used SNPs, while the
identification of potential associations between specific
traits and CNVs has been limited [5–12]. To our best
knowledge, a potential association between IBH and
CNVs has never been studied and CNVs have not yet
been identified in Friesian horses. As CNVs are the lar-
gest source of genetic variation identified in the horse
genome so far [3, 6], CNV-based GWA studies could fa-
cilitate the identification of associations between our
trait(s) of interest and additional genetic variation that is
otherwise undetectable in SNP-based GWA studies.
Moreover, genomic regions associated in CNV-based
GWA studies may reveal more complex structures
underlying phenotypic variation. Therefore, the aim of
this study was to identify CNVs and to perform a
CNV-based GWA study to identify genomic loci associ-
ated with IBH in Friesian horses. A SNP-based GWA
study was performed as well to allow for comparison.
Identification of genomic regions and genes associated
with IBH will increase our knowledge on the aetiology
and will allow for more effective selection aimed at de-
creasing IBH prevalence.
Methods
Phenotypes and horses
Data were gathered through an online inquiry containing
questions about the horse, the farm and IBH. Questions
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concerned among other things clinical symptoms, recur-
rence of symptoms, application of preventive measures
and success of preventive measures that were applied.
Where necessary, questions were clarified with figures
and pictures of horses depicting clinical symptoms on
various parts of the body and of different severity. Devel-
opment of the inquiry was performed in close collabor-
ation with a veterinary expert on diagnosing IBH from
the Veterinary Faculty of Utrecht University. Through
the inquiry, the necessary information was obtained to
discriminate cases and controls. Cases were defined as
Friesian horses showing the typical seasonal appearance
of IBH clinical symptoms. In case preventive methods
were applied, cases were defined as Friesian horses that
will develop symptoms when these methods would
cease. Controls were defined as Friesian horses free of
clinical symptoms. However, in several controls (11.6%)
preventive methods were applied (e.g. a blanket to pro-
tect the horse from any kind of biting insects). Owners
of these horses indicated that, when the preventive
methods would cease, the horse would not develop
symptoms.
A strict protocol was followed to select the horses for
genotyping to increase the reliability of the phenotype.
Controls were carefully selected to ensure exposure to
Culicoides spp. Controls were therefore located on a
farm where at least one case was present (82.6% of the
controls). Not all controls could be collected from farms
with cases present, and the remaining controls were col-
lected from IBH high-risk regions in the Netherlands
(e.g. [27]). Although age at onset of IBH varies greatly
[e.g. [14, 16]], average age at onset is considered to be
between 2 and 4-years-of age. Controls were therefore
required to be at least 4-years-of-age and at least one to
two years at risk of developing IBH clinical symptoms.
Cases showed symptoms preferably during two or more
seasons (90.8% of the cases; Additional file 1) and their
status was confirmed by a veterinarian (60.0% of the
cases). Moreover, both cases and controls were prefera-
bly located for two or more years on their current farm
to ensure a constant management (91.4% of the horses).
Data consisted of 280 Friesian horses, of which 142
were cases and 138 were controls. All horses originated
from the Netherlands. Age and sex distribution was
similar for cases and controls (Additional file 1). Also,
cases and controls descended from a similar number of
ancestors, where 40 sires had both case(s) and control(s)
among their offspring (66% of the data).
DNA extraction, quality and genotyping
DNA was extracted from hair samples that were col-
lected with written permission of the horse’s owner.
DNA was extracted following the standard protocol for
hair roots using the NucleoSpin® Tissue kit from Bioke
(Macherey-Nagel). Concentration of DNA was measured
using the Infinite® M200 and normalized to 10 ng/μl
using Tecan EVO®. Lack of degradation of DNA was
confirmed by electrophoresis, carried out using a 1-ll
sample on 1.5% multi-purpose agarose gels in Tris–bor-
ate–EDTA buffer at 120 V.
Genotypes were obtained using the Axiom® Equine
Genotyping Array containing 670,796 SNPs. Part of the
quality control was performed with Axiom™ Analysis
Suite 1.1 using the default settings of the Best Practices
Workflow. OTV (Off Target Variants) Caller was used to
perform a post-processing analysis to identify miscalled
clustering and to re-label horses in this cluster as OTV
(for 6083 SNPs). Gender and computed gender based on
homozygosity of the X-chromosome matched for all
horses. Subsequent quality control was performed using
PLINK software v1.07 [28, 29]. SNPs with call-rate < 90%
and MAF < 5% were discarded. All horses passed the
call-rate threshold of ≥90%.
The pedigree (A, according to Colleau [30]) and gen-
omic relationships (G, according to VanRaden [31])
among horses was calculated with calc_grm software
[32]. Four horses caused large discrepancies between
pedigree and genomic relationships; their genotype data
was therefore discarded. The multidimensional scaling
plot (Additional file 2) showed that the horses belonged
to one cluster. After all quality checks were performed,
the final genotype dataset to perform a SNP GWA study
contained 276 horses – 141 cases and 135 controls –
and 307,075 SNPs (45.8% of all SNPs present on the
array).
SNP-based GWA study
The significance level of differences in allele frequencies
between cases and controls per SNP was calculated
using a χ2-test with 1df using the assoc and adjust com-
mands in PLINK software v1.07 [28, 29]. Genomic Con-
trol corrected P-values were presented. The conservative
Bonferroni corrected significance level was 1.63 × 10− 7 (
¼ α=n , where α was the desired significance level being
0.05 and n was the number of SNPs (n = 307, 075) that
were tested).
CNV calling
To compute values requested for CNV calling, the files
denominated ‘summary’, ‘calls’ and ‘confidences’ that were
built during SNP genotyping in Axiom™ Analysis Suite
1.1 were used. These files were applied into PennCNV
[33–35] function ‘generate_affy_geno_cluster.pl’ to gener-
ate canonical clusters values [36] for each SNP on the
array. Subsequently, the canonical clusters were used
into the ‘normalize_affy_geno_cluster.pl’ function, which
estimated Log R Ratio (LRR) and population frequencies
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of the B allele (BAF) values for each of the 276 analysed
horses. GC content around each SNP (1 Mb window)
was estimated using the BEDTools ‘nuc’ function [37]
that generated the GCModel file. The GCModel file was
needed to adjust LRR values for genomic waves by the
‘genomic_wave.pl’ function in PennCNV (for genomic
waves bias details, see [33]). To infer BAF values for
each SNP, we applied the ‘compile_pfb.pl’ function on all
276 analysed horses. The file containing these BAF
values was needed to call CNVs with a hidden Markov
model algorithm in PennCNV [33–35] with the
‘detect_cnv.pl’ function using default parameters. All
called CNVs were filtered based on minimum length
(≥1 kb, technical reasons related to SNP density), LRR
SD (≤0.3) and BAF drift (≤0.02). After quality control,
CNV information from the 31 autosomal horse chromo-
somes and 222 horses (111 cases and 111 controls)
remained for the subsequent analysis. Most horses (45
out of 54) were removed based on high BAF drift.
CNV region identification and association
Individual CNVs of the 222 Friesian horses were merged
into CNVRs, i.e. genomic regions in the horse genome
covering CNVs that overlapped by at least 1 bp [38]
using the CNVR building process in CNVRuler [39]. To
minimize the possibility of overestimating the size of
CNVRs, low-density areas were trimmed: the area cov-
ered by < 10% of the total contributing CNVs within a
CNVR was removed using the recurrence option.
A CNV-based case-control association analysis for
IBH – based on all CNVs identified in Friesian horses –
was performed with CNVRuler [39]. The performed ana-
lysis tested for an association between CNVs at a specific
CNVR and the disease status (case or control). Separate
P-values were generated for gains and losses using logis-
tic regression including one principal component as co-
variates to adjust for population stratification (second
and third principal component were not significant, data
not shown). In the end, three association analyses were
performed e.g. considering only gains, only losses or
both gains and losses. That is, the number of cases with
a particular gain (a CNV with more than 2 copies within
a specific CNVR) was compared to the number of con-
trols with this gain. The second analysis only considered
losses (a CNV with less than 2 copies within a specific
CNVR), where again the number of cases with a particu-
lar loss was compared to the number of controls with
this loss. In the analysis concerning both gains and
losses, we compared the number of cases having a CNV
(either gain or loss) within a specific CNVR with the
number of controls having a CNV within this specific
CNVR. We did not relate the number of copies to for
instance the severity of IBH, among other things because
often many horses had the same number of copies.
We graphically represented all copy number events
and respective frequencies in grid of panels implemented
in the Bioconductor R package gtrellis [40]. Due to space
limitation all information shown is based on genomic
windows of 1 Mb.
Gene mapping, enrichment and ontology analysis
The overlap between the CNVRs identified in Friesian
horses and genes annotated in the horse genome
(Ensembl – BioMart: http://www.ensembl.org/biomart/
martview/ and [41]; EquCab2) was determined and clas-
sified into upstream, downstream, equal, encompassing
or inside. The enrichment of overlapping genes was per-
formed based on human orthologues available in Bio-
Mart. The use of human orthologues is justified due to
the still incomplete annotation of genes on the equine
genome [6, 9]. Based on these orthologues, the Cluster-
Profiler Bioconductor R package with the enrichKEGG
function [42] was used to identify KEGG pathways that
were overrepresented in CNVRs.
CNV validation by qPCR
Validation of low frequent CNVs was performed by
quantitative real-time PCR (qPCR) (Additional file 3).
Low frequent CNVs were selected, as these CNVs are
more likely to be false positives compared to CNVs
shared by more horses. We selected 12 individual low
frequent CNV calls based on incidence, size and state, to
sample CNVs from the whole distribution of size and
state. Concerning incidence, unique (private) CNVs and
those present in 2 horses (all with exactly the same
breakpoints) were selected to represent two classes of
low frequent CNVs. Concerning size, for each frequency
class, 6 CNVs were selected based on the size distribu-
tion. A CNV was selected from the minimum, first
quadrant, mean, median, third quadrant and maximum
part of the distribution. Concerning state, in each fre-
quency class we ensured the inclusion of at least one
CNV belonging to each of the common states (0n, 1n
and 3n) (Additional file 3).
To determine the quality of DNA samples to be vali-
dated, the amount of dsDNA was measured with Qubit®
Fluorometer. Subsequently, for each sample we used 4
different concentrations to determine primer efficiency:
15 ng, 7.5 ng, 3.8 ng and 1.9 ng of DNA. Reactions were
assembled in a final volume of 12.5 μl, containing
3.75 μl DNA, 6.25 μl 2X reaction buffer MESA Blue
from Invitrogen™, 1.25 μl forward primer (2 μM) and
1.25 μl reverse primer (2 μM). Samples with a CNV in a
specific region and diploid (2n) reference samples were
tested with the designed primersets (Additional file 3).
Measurements were performed with the Applied Biosys-
tems® 7500 real-time PCR system. Cycle thresholds (log2
Ct) were corrected for primer efficiency. ΔCt was
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calculated as Ct from the sample with a specific CNV
minus Ct of the diploid (2n) reference sample [43]. The
reference sample was given by a random horse with 2n
state. As it is challenging to determine the exact state of
a CNV with data from SNP-arrays, we considered a
CNV validated when its state (loss or gain) was equal.
Identification of novel CNVRs
We determined the overlap between CNVRs identified
in the Friesian horse population and equine CNV(R)s
already published in scientific literature [3–9, 11, 12]. It
allowed us to identify CNVRs that had not been discov-
ered so far (i.e. = novel CNVRs) and CNVRs that are
shared across breeds. CNVRs among studies were con-
sidered to overlap when at least 1 bp was in common
and were considered the same event (that is, the same
CNVR) when the mutual overlap was > 70%.
Results
SNP-based GWA study
The SNP-based GWA study showed a clear association
between a region on ECA20 and IBH in Friesian horses
(Fig. 1). Regions with a suggestive association (P-value <
0.0001) were identified on ECA2, 9, 10 and 11. In total 2
SNPs passed the Bonferroni corrected significance level
(Additional file 4). The SNP most significantly associated
with IBH (P-value = 7.41 × 10− 7) and of good quality was
AX-103894624 located on ECA20:31,245,645 (Add-
itional file 5). Estimated odds ratio was 2.62 (allele sub-
stitution effect β = ln (OR) = 0.96). The IBH-associated
allele frequency was 0.46 in cases and 0.25 in controls.
CNV and CNVR detection
In total, 15,041 CNVs were detected in 222 horses of
which 85.5% were gains and 14.5% were losses (Fig. 2,
Additional file 6). Number of CNVs per horse ranged
from 18 to 262 (mean = 67.8; median = 53.5). Number of
SNPs per CNV ranged from 3 to 483 (mean = 15.1; me-
dian = 8). Size of the CNVs ranged from 1017 bp to
2.73 Mb (mean = 61.7 kb; median = 29.8 kb). Most CNVs
were detected on ECA20, where chromosomal coverage
was 11.5% (Additional file 6). CNVs were detected on all
autosomes (Additional file 6).
Overlapping CNVs were concatenated into 5350
CNVRs (Additional files 6 and 7). CNVRs encompassing
both losses and gains in different horses corresponded
to 3.2% (Additional file 6), while only losses corre-
sponded to 2.1% and only gains to 94.7% of all identified
CNVRs. Size of the CNVRs ranged from 123 bp to
1.04 Mb (mean = 46.8 kb; median = 29.3 kb). Although
the minimum length of a CNV was set to 1 kb, several
CNVRs turned out to be < 1 kb due to trimming of
low-density areas as described in the Methods section.
Chromosomal coverage (percentage of a chromosome
covered by CNVRs) was highest for ECA17 (16.2%),
followed by ECA26 (16.0%) and ECA12 (15.1%). We did
not find a relation between the number of SNPs on a
chromosome and chromosomal enrichment for CNVRs
(Additional file 6). Coverage of the total genome by
CNVRs was 11.2%. In total 1949 CNVRs (36.4%) were
shared by at least 2 horses. Mean size of shared CNVRs
(79.3 kb) was larger compared to mean size of unique
CNVRs (private, 28.2 kb) and 49.2% of CNVRs involved
genes (Additional files 6 and 7).
Fig. 1 Manhattan plot of insect bite hypersensitivity in Friesian horses based on a SNP-based genome-wide association study. Significance level
based on allele frequency differences between cases (n = 141) and controls (n = 135) using a χ2-test (1df). The horizontal red line is the Bonferroni
corrected significance level (P-value = 1.63 × 10−7)
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Association of CNVs with IBH
In total 19 CNVs were associated with IBH (P-value <
0.05, Table 1, Additional file 8), but did not reach
genome-wide significance. CNVs within a specific CNVR
on ECA10 (12,948,489 to 13,075,518 bp) had the lowest
P-value in the association test (P-value = 0.0003), was
127,030 bp in size and included both gains and losses. A
CNV within this specific CNVR was observed in 25
cases (15 gains and 10 losses) and 6 controls (all gains)
with an odds ratio (OR) of 5.92 (Table 1). CNVs (gains)
within a specific CNVR on ECA20 had the lowest
P-value in the association test based only on gains
(P-value = 0.001; 30,624,048 to 30,689,273 bp) and was
65,226 bp in size. A CNV (gain) within this specific
CNVR was observed in 60 cases and 35 controls with an
OR of 2.65 (Table 1). CNVs (losses) within a specific
CNVR on ECA20 (30,743,179 to 30,775,429 bp) had the
lowest P-value in the association test based only on
losses (P-value = 0.008) and was 32,251 bp in size. A
CNV (loss) within this specific CNVR was observed in
18 cases and 5 controls with an OR of 2.45 (Table 1). In-
dividual CNVs within the CNVRs with the lowest
P-value in the association tests are visualized in Add-
itional file 9. Candidate genes located within CNVRs in
which CNVs were associated with IBH are presented in
Table 1.
The CNV-based GWA study results showed that IBH
in Friesian horses is associated with CNVs within spe-
cific CNVRs on several autosomes. In total 7 out of 19
CNVRs in which CNVs were associated with IBH were
Fig. 2 Distribution of polymorphic CNVRs in the Friesian horse genome. Somatic horse chromosomes containing CNV regions with their
frequency. The grey bars represent regions harbouring losses and gains concomitantly, the green bars exclusively gains and the magenta bars
exclusively losses. The genomic interspersed regions without CNVRs are represented in white. Polymorphic CNVRs: the bars indicate the CNVRs
with at least 3 CNVs mapped in 3 different horses (i.e. 1 % of frequency). log10 CNV-sample: the log10 of the number of horses containing a CNV
event throughout the genome, indicated as a distribution in white
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located on ECA20 encompassing the MHC class I, II
and III region. These CNVRs identified on ECA20 did
correspond to the associated region on the same
chromosome identified with the SNP-based GWA study
(Table 1 and Additional file 5).
Biological pathways affected by CNVRs
The biological pathways enriched in the identified
CNVRs were mainly related to sensory perception, me-
tabolism and immunity (Fig. 3). The pathway with low-
est P-value was Olfactory transduction (hsa04740,
P-value = 1.4 × 10− 22) followed by Natural killer cell me-
diated cytotoxicity (hsa04650, P-value = 1.9 × 10− 8) and
Autoimmune thyroid disease (hsa05320, P-value =
0.0006). The pathways that we identified were in agree-
ment with previous CNV studies in horses and in other
mammals (e.g. [2, 6]), that identified these olfactory re-
ceptors, metabolism and immunity related genes as
CNV hotspots.
CNV validation and identification of novel CNVRs
Validation of low frequent CNVs by qPCR indicated that
state and copy number of 50% of private CNVs were
exactly validated. Also, 66% of the CNVs shared by two
horses were validated, where state of the CNV was vali-
dated in 50% and state and copy number were validated
in 16.7% (Additional file 3).
When looking at the CNVs within 19 CNVRs in Frie-
sian horses significantly associated with IBH, 17 of these
regions were also found in one or more horse populations
presented in the literature (Additional file 10). Out of
these 17 regions, only one was considered a different
event as the overlap between the CNVR identified in Frie-
sian horses and the region presented in literature was
smaller than 70% (50.2%, CNVR4271; Additional file 10).
In total 16 out of 17 CNVRs were considered the same
event (that is, the same CNVR) as the region presented in
literature. For all these 16 CNVRs, the region identified in
Friesian horses completely overlapped with CNV(R)s pre-
sented in literature (Additional file 10).
In total 3105 out of 5350 CNVRs were novel (58.0%),
that is, so far only identified in the Friesian horse popu-
lation. 42.0% of the CNVRs were also found in one or
more horse populations presented in literature (that is,
at least 1 bp overlap).
Discussion
To date, CNVs have been shown to explain the largest
part of genetic variation in genomes of many species in-
cluding the horse [3, 6]. As such, CNVs are likely to fur-
ther contribute to our understanding of the equine
genome and its expression. Although the efficiency of
CNV identification using SNP arrays is lower compared
to CNV focussed arrays (e.g. CGH array), the results of
Fig. 3 Biological pathways enriched in CNVRs detected in Friesian horses. Biological pathways enriched in CNVRs detected in 222 Friesian horses.
To compose the gene enrichment, we used human orthologues (Ensembl – BioMart, [41]) of genes overlapping CNVRs. The y-axis indicates the
enriched KEGG pathway. The x-axis the ratio between the number of analysed genes and the number of genes in each KEGG pathway presented
on the y-axis. The ‘Adjusted p-value’ heatmap represents the enrichment P-value for each pathway corrected for false discovery rate (FDR, [60]).
The circle size represents the number of genes in each pathway
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the current analyses were comparable to previously pub-
lished equine CNV studies that predominantly utilized
CNV focussed arrays. The chromosomes with the highest
CNV distribution (that is, number of CNVs) in this study
were ECA1, 12, and 20, the same chromosomes as identi-
fied by Dupuis and colleagues [5], Doan and colleagues
[3], Metzger and colleagues [9], Ghosh and colleagues [6]
and Wang and colleagues [11]. Chromosomes with the
greatest coverage by CNVRs were ECA12, 17, and 26,
with multiple previous studies also identifying ECA12 [3,
6, 9, 11]. The fraction of the genome covered by CNVRs
in our study (11.2%) was higher than previously published
by Doan and colleagues [3, 4], Dupuis and colleagues [5],
Ghosh and colleagues [6] and Wang and colleagues [11],
yet similar to the genome coverage obtained by Metzger
and colleagues [9] using PennCNV and 50 k SNP genotyp-
ing data. However, CNV and CNVR metrics (e.g. number
and size) from equine CNV studies are highly diverse.
Ghosh and colleagues [6] composed a CNV dataset for
the horse genome based on all published equine CNV
data at that time [3–6, 9, 11, 44]. Noticeably, CNV data
were included irrespective of the CNV discovery platform
used, the analytical methods applied, and the (sometimes
limited) number of breeds and individuals. Differences in
CNV metrics between the studies also arose from experi-
mental differences [6]. Indeed, the number of CNVs iden-
tified in the same horse population differed greatly
depending on the CNV detection algorithm that was used,
whereas the overlap in detected CNVs was also limited
[9]. The composite CNV dataset contains 1476 CNV re-
gions (CNVRs). The majority of these CNVRs were
study-specific, while 20% were shared between two or
more studies [6].
Recently, data from more contemporary studies were
added [7, 8, 10, 12] and indicated that 58.0% of the
CNVRs identified in Friesian horses can be considered
novel CNVRs. However, Friesian horses are genetically
somewhat more inbred and distant to the other investi-
gated breeds as indicated by previous research on gen-
etic diversity in several horse breeds using Short
Tandem Repeat loci [45] and SNP data (unpublished
data). Therefore, novel CNVRs could be expected and
may reflect, in part, variants associated with specific ad-
aptations or with breeding goal traits in Friesian horses.
Nonetheless, validation of CNVs is needed in order to
conclude if identified CNVs should be considered true
structural variants. The state (gain or loss) of low fre-
quent CNVs (private or shared by two horses only) of
various lengths was validated for 58.3% of the tested
CNVs. Both state and copy number were validated for
33.3% of the tested CNVs. Metzger and colleagues [9]
validated state and copy number of 91.7% CNVs through
qPCR, but their choice of CNVs to be validated was
non-random as only common CNVs associated with
body size were selected. Although no attention was paid
to incidence, size and state, Pawlina-Tyszko and col-
leagues [12] randomly selected 12 CNVs using qPCR.
Identical validation results were obtained, as both state
and copy number were validated for 33.3% of the tested
CNVs and state was validated for 58.3%. Validation,
characterization and sharing of identified structural vari-
ants like CNVs is encouraged as a way to increase our
understanding of the equine genome and its expression.
Many traits of interest in horses, as well as common
and relevant diseases affecting equine welfare have not
been tested in light of structural variants. Only a limited
number of studies [3, 5–12] have attempted to detect as-
sociations between CNVs and a specific trait, a disease
or gene expression in horses. In many studies, no associ-
ation or inconclusive associations were found, likely due
to the number of horses with the phenotype or the spe-
cific CNV having been (very) limited. To our best know-
ledge, we were the first to perform a CNV-based
case-control association study for IBH. Most CNVs
within specific CNVRs that we found to be associated
with IBH were also identified in other horse popula-
tion(s) [3–9, 11], increasing the likelihood of these CNVs
being true structural variants. Several CNVs within or
surrounding the major histocompatibility complex re-
gion (MHC, or ELA in horses) on ECA20 were associ-
ated with IBH in Friesian horses. Some of these CNVs
contained MHC class I associated genes (e.g. BTN3A3)
involved in T cell mediated immunity. Similarly, the
SNP-based GWA study and all previous studies on IBH
using SNP data to date have identified this region [16,
18, 19, 23]. However, we obtained the lowest P-values
thus far likely due to an increase in power caused by the
large number of inbred horses that were investigated
with the high density SNP array combined with a strict
protocol to select cases and controls.
Furthermore, serological research established an asso-
ciation between MHC antigens and IBH [24, 25]. MHC
class I and II evoke immune responses by recognizing
many foreign molecules, whereas MHC class III encodes
for complement components and specific cytokines (e.g.
TNF-α, [46–48]. The MHC region contains genes that
have critical functions in immunity, in both the adaptive
and innate immune systems (e.g. [46, 49]). In verte-
brates, the MHC region is the most gene-dense region
of the genome (e.g. [50, 51]). Genes within this region
are extremely polymorphic. In an attempt to explain this
unusually high diversity, several hypotheses founded on
disease-based and reproductive mechanisms have been
formulated (as reviewed by [52, 53]). One such hypoth-
esis is the overdominance (or heterozygote advantage)
hypothesis, which states that MHC diversity is main-
tained by balancing selection for millions of years
reflecting “the long-standing battle for supremacy
Schurink et al. BMC Genetics  (2018) 19:49 Page 9 of 13
between our immune system and infectious pathogens”
(as expressed by [51]). Loss of diversity in these genes
seems to reduce the ability to cope with diseases [54]
with associations between MHC polymorphisms and fit-
ness having been detected (as reviewed by [52, 53]). Al-
though our knowledge on MHC, its polymorphisms,
diversity, and expression continues to increase, there is
still much to elucidate. Results of the SNP- and
CNV-based GWA studies suggest that the MHC region
is associated with IBH. Recently Lanz and colleagues [55]
showed that IBH and airway hyperreactivity in horses
were associated and discussed the potential of a (partly)
common immunogenetic background. The regions identi-
fied to be associated with IBH (including MHC) might
therefore underlie other equine hypersensitivities as well.
Our CNV-based GWA study reflects a first attempt in as-
sociating IBH with variants other than SNPs. While valid-
ation is still needed to verify the contribution of these
CNVs to IBH, it appears that not only nucleotide differ-
ences contribute to IBH sensitivity but more complex,
structural variations like CNVs also play a role.
Genetic variation is what makes each individual unique
and can determine a unique sensitivity to a specific dis-
ease. An abundance of SNPs has been identified in many
species, and SNPs associated with specific diseases and
other phenotypes have been found. Besides the MHC class
I, II and III region on ECA20, promising regions likely to
hold gene(s) contributing to IBH sensitivity were located
on ECA9, 10 and 11 (based on the SNP-based GWA study
and [16–19]). However, more in depth research (e.g. se-
quencing) is needed to be able to identify and validate var-
iations contributing to IBH sensitivity. During the last
decade, CNVs proved to be a prevalent form of variation
in many species, ultimately responsible for a substantial
proportion of the total genetic variability in populations
that contributes to a variety of phenotypes. The import-
ance of CNVs has been recognized in modulating gene ex-
pression and disease phenotype with associations having
been established for autoimmune diseases [56], asthma
[57], and obesity [58, 59]. Both CNV and SNP analyses
identified an association between the MHC region on
ECA20 and IBH (this study and [16–19]). However, CNVs
associated with IBH in Friesian horses were not often in
close proximity to SNPs previously identified to be associ-
ated with IBH. Although this study comprises a first at-
tempt to associate structural variants in the equine
genome with IBH, the associated CNVs potentially repre-
sent additional regulators of IBH providing further evi-
dence that IBH is a multifactorial polygenic disease with a
complex genomic architecture.
Conclusions
In conclusion, CNVs were identified in a sample of the Frie-
sian horse population and results were comparable to
previously published equine CNV research. Characterization
and sharing of identified CNVs within various horse breeds,
including the Friesian horse breed, contributes to our know-
ledge on structural variants in horses and enhances our un-
derstanding of the equine genome and its phenotypic
expression. Results of the association analyses showed that
not only do nucleotide differences appear to contribute to
IBH sensitivity, but more complex, structural variations like
CNVs are also highly likely to be involved. IBH can therefore
be considered as a multifactorial polygenic disease with a
complex genomic architecture.
Additional files
Additional file 1: Characteristics of the investigated Friesian horses.
Characteristics of the investigated cases concerning preventive methods
and the observed, seasonality of clinical symptoms. And characteristics of
the investigated cases and controls, where mean age, number of males
and females, and pedigree of investigated cases, controls and of the total
investigated Friesian horse population are presented. (DOCX 13 kb)
Additional file 2: Multidimensional scaling plot of 276 genotyped
Friesian horses. Multidimensional scaling plot of 276 genotyped Friesian
horses calculated with cluster and mds-plot commands in PLINK software
v1.07 [28, 29] using autosomal SNPs. (DOCX 31 kb)
Additional file 3: CNVs randomly selected based on incidence and size
validated through qPCR. CNVR identification, chromosome (ECA), start
and end position (in bp) and size of the CNVs in the investigated
Friesians horse sample is presented, including information on whether the
CNV concerned a private (present in 1 horse) or shared (present in 2 horses;
the exact same breakpoints were observed) CNV. The designed primers,
state of the CNV and results of the qPCR are given. (DOCX 14 kb)
Additional file 4: Regional association plot (ECA20) of insect bite
hypersensitivity in Friesian horses. Significance level based on allele
frequency differences between cases (n = 141) and controls (n = 135)
using a χ2-test (1df). The horizontal red line is the Bonferroni corrected
significance level (P-value = 1.63 × 10− 7). (DOCX 27 kb)
Additional file 5: SNPs most significantly associated with insect bite
hypersensitivity in Friesian horses. SNPs most significantly associated with
insect bite hypersensitivity including chromosome, position (in basepairs),
SNP name, P-value, odds ratio (OR) and allele frequency in cases and
controls. SNPs marked grey passed the Bonferroni corrected significance
level (P-value = 1.63 × 10− 7). (DOCX 14 kb)
Additional file 6: Chromosomal distribution, characteristics and
enrichment of detected CNVs and CNVRs. Number of CNVs and CNVRs
detected per Equus caballus chromosome (ECA), including detection,
state, content, mean size (in base pairs), coverage (in base pairs),
chromosomal distribution (¼ number of CNVs per chromosometotal number of CNVs  100%),
chromosomal coverage (
CNVR coverage per chromosome
length of chromosome  100%) and SNP
coverage in base pairs (¼ length of chromosomenumber of SNPs per chromosome). (DOCX 24 kb)
Additional file 7: 5350 CNVRs detected by CNVRuler based on 15,041
CNVs identified by PennCNV in 222 Friesian horses. 5350 CNVRs detected
by CNVRuler based on 15,041 CNVs identified in PennCNV [33–35] in 222
Friesian horses. Information that is presented includes CNVR identification
(CNVR_ID), Equus caballus chromosome (ECA), start position (in bp), end
position (in bp), size (in bp), copy number state, number of horses (N)
with CNVR and whether the CNVR includes a gene(s) and is present in 1
horse (private) or more (shared). The gene(s) located within the CNVR
were identified using human orthologues. Start and end position of the
genes annotated in the horse genome are presented, including Ensembl
IDs and whether the CNVR is upstream, inside, downstream of the gene
or encompasses the gene. (XLSX 603 kb)
Additional file 8: Genome-wide CNV and SNP association plots of
insect bite hypersensitivity in Friesian horses. Genome-wide CNV and SNP
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association plots of IBH in 222 Friesian horses. The –log10 P-value is
plotted against the chromosomal location (start position) of CNVs within
a specific CNVR and each SNP tested across all chromosomes. The
horizontal red line indicates a P-value of 0.05 for CNVs within a specific
CNVR and the Bonferroni corrected significance level (P-value = 1.63 ×
10− 7) for SNPs. Transparent vertical bars are included to be able to
compare the GWA results. A) CNV association plot based on an analysis
taking into account both gains and losses. B) CNV association plot based
on an analysis taking into account gains only. C) CNV association plot
based on an analysis taking into account losses only. D) SNP association
plot, for comparison purposes. (DOCX 147 kb)
Additional file 9: Visualization of individual CNVs within the CNVRs with
the lowest P-value in the association tests. Visualization of individual
CNVs within the CNVR on ECA10:12,948,489-13,075,518 (association test
including both gains and losses), ECA20:30,624,048-30,689,273
(association test including gains only) and ECA20:30,743,179-30,775,429
(association test including losses only). Each row represents one horse
and the X-axis is the position on the chromosome. The black line marks
the location of the CNVR. Blue lines represent controls, red lines cases. A
dotted line represents a deletion (state = 0n), a striped line represents a
CNV with state equals 1n and a solid line represents a duplication (3n).
(DOCX 50 kb)
Additional file 10: Overlap between CNVs within specific CNVRs
associated with IBH in Friesian horses and CNV(R)s already published in
literature. Overlap between CNVs within specific CNVRs associated with
IBH (n = 19) and CNV(R)s already published in literature. CNVR
identification, chromosome (ECA), start and end position (in bp) and size
(in bp) of the CNVR is presented. It is indicated how the CNVR in Friesian
horses overlapped with the CNV(R)s already published in literature
(classification) and how great the overlap of the CNVR in Friesian horses
was with literature (in percentage and bp). (DOCX 16 kb)
Abbreviations
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